Nearly a century after Alexander Fleming watched a stray mold colony dissolve the Staphylococcus on his laboratory plate, that same organism now resists drug classes developed to disrupt cell wall synthesis, ribosomal protein production, DNA gyrase activity, and membrane integrity including penicillins, cephalosporins, fluoroquinolones, and vancomycin. Methicillin-resistant Staphylococcus aureus (MRSA), which carries the mecA gene encoding an alternative penicillin-binding protein that sidesteps beta-lactam attack, causes hospital-acquired bloodstream infections, surgical-site infections, and pneumonia worldwide, and belongs to the ESKAPE group: six bacterial genera defined by their capacity to evade multiple antibiotic classes. The 2024 Global Research on Antimicrobial Resistance (GRAM) study projects that Drug-resistant infections will directly kill more than 39 million people between 2025 and 2050, with resistant Staphylococcus aureus (S. aureus) infections linked to approximately 130,000 deaths in 2021 alone; South Asia bears the heaviest projected burden, at an estimated 11.8 million deaths.
The standard of care for confirmed MRSA infection rests on a narrow formulary. Vancomycin, a glycopeptide that disrupts cell-wall crosslinking, has served as the clinical anchor since the 1950s, but vancomycin-intermediate S. aureus (VISA) and vancomycin-resistant S. aureus (VRSA) strains have steadily eroded its reliability, and second-line agents — daptomycin, linezolid, ceftaroline, and dalbavancin — address the same handful of biological pathways that S. aureus has had decades to defend against. Identifying a target that approved antibiotics have left largely untouched, where resistance mutations are therefore scarce, has become a central objective in antimicrobial drug discovery.
Why is thymidine kinase an attractive antibiotic target in S. aureus?
Thymidine kinase (TK) is a small enzyme in the bacterial pyrimidine salvage pathway that phosphorylates thymidine to thymidine monophosphate (TMP), a nucleotide building block essential for DNA synthesis and repair. Genetic studies have flagged TK as essential in S. aureus: strains in which TK activity is abolished lose viability. Because no approved antibiotic targets TK, the enzyme has not faced the sustained selection pressure that drives resistance mutations in established targets such as penicillin-binding proteins or DNA gyrase, making it an untested template for drug design.
A 2025 study tested whether TK's essentiality and antibiotic-naivety translate into a druggable vulnerability. Researchers at Indian Institute of Technology Gandhinagar (IITGN), with colleagues at Jamia Millia Islamia, Jamia Hamdard, Xi'an Jiaotong-Liverpool University, and the Ahmedabad-based company Sushen Medicamentos, designed and screened synthetic molecules against the S. aureus TK active site.
"Most antibiotics attack bacteria through a handful of familiar routes, including puncturing their walls and jamming their protein-making machinery. The trouble is that bacteria have spent decades learning to dodge those blows," said Bhaskar Datta, corresponding author of the study and a professor of Chemistry, Biological Sciences and Engineering departments at IITGN. "Antibiotic resistance is, in many ways, an evolutionary arms race. That is why researchers hunt for fresh points of attack."
Combining two battle-tested scaffolds into a new TK inhibitor
The IITGN-led team built their compounds from two established pharmacophores. The sulfonamide functional group inhibits folic acid synthesis in bacteria through competitive blockade of dihydropteroate synthase. The thiazole ring, a five-membered heterocycle containing nitrogen and sulfur, appears in several approved antibacterial drugs and disrupts bacterial function by, among other mechanisms, inhibiting DNA gyrase; the researchers fused both groups into a hybrid thiazolyl benzenesulfonamide framework and directed the resulting compounds toward the TK active site.
The team synthesized nine thiazolyl benzenesulfonamide derivatives, varying aromatic ring substituents to alter the physicochemical properties and binding geometry of each compound, and characterised them by ¹H and ¹³C nuclear magnetic resonance spectroscopy. To rank candidates before running laboratory experiments, they performed molecular docking with AutoDock Vina against the crystal structure of TK from the multidrug-resistant Col strain of S. aureus, which Md. Imtaiyaz Hassan's group at Jamia Millia Islamia had solved and published in Biochimica et Biophysica Acta. That structure gave the team an atomic-resolution map of the ATP-binding pocket: the site where TK captures its phosphate-donor substrate and the primary region they aimed to block.
Among the nine candidates, compound DSA3 — an iodo- and trifluoromethyl-substituted thiazolyl benzenesulfonamide — produced the strongest predicted binding geometry and interaction energy within the ATP-binding pocket. Docking poses placed DSA3 in contact with residues critical to enzyme function, including the catalytic glutamate at position 89 (Glu89) and contact points at Lys43, Lys21, Ser22, Gly20, Phe18, Pro44, and Asp47. Molecular dynamics simulations confirmed that the enzyme–DSA3 complex held stable, with DSA3 inducing minimal conformational change in the protein architecture.
DSA3 inhibits S. aureus thymidine kinase and kills the bacterium in vitro
DSA3 reduced Staphylococcus aureus TK catalytic activity to half its baseline at a concentration of 6.996µM, and two independent biophysical techniques confirmed direct enzyme engagement. Fluorescence spectroscopy detected changes in TK's intrinsic emission on DSA3 addition, consistent with binding near a fluorescent residue. Isothermal titration calorimetry (ITC) then measured the thermodynamic signature of that interaction, characterized by an exothermic and spontaneous complex formation with favorable enthalpy and entropy terms, confirming that DSA3 bound TK through energetically driven contact rather than non-specific association.
In laboratory growth assays, DSA3 inhibited S. aureus proliferation and, at higher concentrations, killed the organism outright. A substantial drop in colony-forming units at the minimum inhibitory concentration confirms the effect is bactericidal, not merely bacteriostatic.
Key findings from the DSA3 characterisation study include:
- Target: Thymidine kinase (TK) from the pyrimidine salvage pathway of Staphylococcus aureus
- Scaffold: Iodo- and trifluoromethyl-substituted thiazolyl benzenesulfonamide (compound DSA3), assembled from pharmacophoric components with established antibacterial precedent
- Binding site: ATP-binding pocket of Sa-TK, with key contacts at Glu89 (catalytic residue), Lys43, Lys21, Ser22, Gly20, Phe18, Pro44, and Asp47
- Enzyme inhibition: IC₅₀ of 6.996 µM confirmed by activity assay
- Biophysical confirmation: Fluorescence spectroscopy and ITC demonstrate spontaneous, exothermic binding
- Antibacterial outcome: Growth inhibition and bactericidal activity against S. aureus demonstrated in vitro
- Development stage: Early preclinical; proof-of-concept scaffold, not a clinical candidate
How does DSA3 compare to existing MRSA treatments and pipeline compounds?
DSA3's molecular target, TK, sits at the entry point of the pyrimidine salvage pathway, upstream of thymidylate kinase (TMPK), and no approved antibiotic class has yet exploited it; TMPK has attracted growing interest for MRSA drug design, with a 2025 virtual screening campaign identifying candidate inhibitors, though none have cleared biochemical validation in cells. The canonical sulfonamide target, dihydropteroate synthase in the folate pathway, remains clinically exploited through trimethoprim–sulfamethoxazole combinations, but rising resistance rates show its limits. TK's essentiality and its freedom from prior antibiotic pressure distinguish it from both comparators as a drug target.
| Modality | Target / Mechanism | Development status | Key limitation |
|---|---|---|---|
| Vancomycin | Cell wall crosslinking (D-Ala–D-Ala terminus) | Approved, first-line MRSA | VISA and VRSA strains eroding utility |
| Linezolid | 50S ribosomal subunit (protein synthesis) | Approved, second-line | Myelosuppression; linezolid-resistant strains emerging |
| Daptomycin | Membrane depolarisation | Approved, second-line | Reduced susceptibility with prolonged use |
| Ceftaroline | PBP2a (modified penicillin-binding protein) | Approved, MRSA-active cephalosporin | Resistance reported in some clinical isolates |
| Exebacase (bacteriophage lysin) | Cell wall peptidoglycan hydrolysis | Phase 3 halted (DISRUPT trial stopped for futility, 2022) | Failed to improve outcomes vs. antibiotics alone in MRSA bacteremia |
| TMPK inhibitors (virtual screening hits) | Thymidylate kinase (pyrimidine salvage) | Early preclinical | Not yet biochemically validated in cells |
| DSA3 (this study) | Thymidine kinase (pyrimidine salvage, upstream of TMPK) | Early preclinical proof of concept | Potency requires improvement; selectivity versus human TK not yet established |
India's AMR policy frameworks provide the strategic context for this research
Funding came from the Indian Council of Medical Research (ICMR), Department of Health Research, and the work fits within two national policy frameworks: India's National Action Plan on Antimicrobial Resistance 2.0 (NAP-AMR 2.0) and the National One Health Mission, both of which prioritise building domestic antibacterial discovery capacity. The One Health framework underpinning these initiatives recognises that resistant pathogens spread across people, animals, and the environment as a single interconnected system. South Asia's projected AMR mortality burden of 11.8 million deaths through 2050 gives particular urgency to developing antibiotic candidates within the region rather than importing them from Europe or North America.
"We have previously reported on using distinctive strategies and less-explored targets to fulfil the larger goal these frameworks set out," said Bhaskar Datta. "As part of our continuing efforts here we have shown that a particular chemical class can engage an underused antimicrobial target in a specific, measurable way."
Rajesh K. Hadiya, co-first author and a former doctoral researcher at IITGN who held the Science and Engineering Research Board–Confederation of Indian Industry (SERB-CII) Prime Minister's Fellowship, was candid about what the results do and do not yet show. "We see DSA3 as a proof of concept and a starting scaffold. It is not a drug," Hadiya said. "Its potency needs to improve, and the future steps include testing against resistant clinical isolates, checking selectivity over the human enzyme, and moving into animal models. But that is exactly where medicinal chemistry begins."
Structure–activity relationship work and selectivity testing will define DSA3's path forward
The IITGN-led team's immediate priorities are structure–activity relationship (SAR) work to push DSA3's potency from the low-micromolar range into nanomolar territory, and modification of the iodo and trifluoromethyl substituents to improve metabolic stability and selectivity over human thymidine kinase 1 (hTK1); active derivatives will then face testing against clinically relevant MRSA isolates and other ESKAPE-associated strains before any advance into rodent infection models. Establishing that DSA3 analogues preferentially inhibit the bacterial enzyme over hTK1 is an essential prerequisite for a viable therapeutic window. If those preclinical checkpoints are cleared, the work could deliver both a validated drug target and a chemically tractable lead series for the broader antimicrobial research community.
This article is based on a press release issued by IITGN was produced under Drug Discovery News' AI Editorial Guidelines.
